NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats.
about
Unprecedented therapeutic potential with a combination of A2A/NR2B receptor antagonists as observed in the 6-OHDA lesioned rat model of Parkinson's diseasePostsynaptic density protein 95-regulated NR2B tyrosine phosphorylation and interactions of Fyn with NR2B in levodopa-induced dyskinesia rat modelsDiscovery of 3-substituted aminocyclopentanes as potent and orally bioavailable NR2B subtype-selective NMDA antagonists.Novel pharmacological strategies for motor complications in Parkinson's disease.Diversity in NMDA receptor composition: many regulators, many consequences.Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potentialRepetitive transcranial magnetic stimulation (rTMS) improves behavioral and biochemical deficits in levodopa-induced dyskinetic rats model.Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.Levodopa-induced dyskinesias in Parkinson's disease: emerging treatmentsTherapeutic potential of targeting glutamate receptors in Parkinson's disease.NMDARs in neurological diseases: a potential therapeutic target.Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.Treatment of the later stages of Parkinson's disease - pharmacological approaches now and in the future.Design, Synthesis, and Biological Evaluation of 3-Benzazepin-1-ols as NR2B-Selective NMDA Receptor Antagonists.Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia.Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.GluN2B antagonism affects interneurons and leads to immediate and persistent changes in synaptic plasticity, oscillations, and behaviorGluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic ratsNMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients.Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.Design, Synthesis, Pharmacological Evaluation and Docking Studies of GluN2B-Selective NMDA Receptor Antagonists with a Benzo[7]annulen-7-amine Scaffold.
P2860
Q28542729-890F21DF-E851-4E09-81B7-26095B5762E2Q34783370-116C0921-7073-48CA-B031-A31414482E36Q36015381-FC5C623F-35A0-44A1-9916-E269A7BFE44CQ36120761-FCF5729A-3A62-4DA4-85E1-554FC6EFB1E1Q36597018-E89CCB85-AF53-4A77-83E4-D41B53BE145BQ37548763-40DE232C-A927-4B58-BDF0-DA551833B922Q37644775-495CBDE2-D5CE-425B-93F1-286CAA589022Q38056852-78681DDE-BF08-44D5-B190-7DF55BFC41C1Q38156760-AAB17B92-602E-42EA-A0CC-7A39044E81EEQ38190016-D9EBDAEE-43C0-4269-86D3-AB6E52306473Q38232734-6D08BE31-AF9A-4860-8A00-9F951A173FBBQ38262418-6F8CEC17-5EF4-4565-B8B0-889AF5CCF67EQ38478999-AD91D2D9-7BF6-46F9-A351-27C62FD1D05FQ39722433-02CAFBAE-0F47-49D0-A121-35F9B1C1CA15Q39801798-C8F03816-3DE8-43F0-B7D1-8C8E86E16341Q40053132-3F6F591C-4D94-47BF-8BCD-555443EE777FQ40778694-5D1678C2-BFED-45DB-B60C-CDD87F1409F1Q40789803-78F638FC-03FC-4B42-B242-18A6377BD17DQ41420806-C08A695D-ECFC-4B4D-B1B4-FC3A8CF76F09Q43067885-6B988C00-7E41-45BD-8AF6-288BA9CFBBBFQ48021684-FD55F3A7-F9BC-4E83-9F36-1A51A26778AD
P2860
NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
NR2B selective NMDA receptor a ...... ons in hemi-parkinsonian rats.
@en
NR2B selective NMDA receptor a ...... ons in hemi-parkinsonian rats.
@nl
type
label
NR2B selective NMDA receptor a ...... ons in hemi-parkinsonian rats.
@en
NR2B selective NMDA receptor a ...... ons in hemi-parkinsonian rats.
@nl
prefLabel
NR2B selective NMDA receptor a ...... ons in hemi-parkinsonian rats.
@en
NR2B selective NMDA receptor a ...... ons in hemi-parkinsonian rats.
@nl
P2093
P1433
P1476
NR2B selective NMDA receptor a ...... ons in hemi-parkinsonian rats.
@en
P2093
P304
P356
10.1016/J.NEUROPHARM.2004.03.011
P577
2004-08-01T00:00:00Z